Intravenous tramadol is used for managing moderate to moderately severe pain in adults.
Cipla share price added more than 2 % in the morning trade today after the pharmaceutical major announced submission of application for intravenous (IV) tramadol with USFDA.
Avenue Therapeutics Inc submitted a new drug application to the US Food and Drug Administration (USFDA) for IV tramadol for managing moderate to moderately severe pain in adults, the company said in a release.
The application is based on positive results from two Phase 3 clinical efficacy and safety trials in patients following bunionectomy and abdominoplasty surgeries, as well as an open-label safety study of more than 500 patients who received the 50 mg dosing regimen, it added.
At 09:31 hours, Cipla was quoting at Rs 461.00, up Rs 11.30, or 2.51 %, on the BSE.
Our Best Ever Services - Nifty Future Tips | Stock Cash Tips
For Quick Trial – 62329-95233 | or mail us here:info@thegrssolution.com
or visit www.thegrssolution.com
